Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
OPHT's Cash to Debt is ranked higher than
75% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPHT' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.14
OPHT's Equity to Asset is ranked lower than
91% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OPHT: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
OPHT' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.20 Max: 0.27
Current: 0.14
0.14
0.27
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
65% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 1.29
M-Score: 10.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -239.84
OPHT's Operating margin (%) is ranked lower than
63% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. OPHT: -239.84 )
Ranked among companies with meaningful Operating margin (%) only.
OPHT' s Operating margin (%) Range Over the Past 10 Years
Min: -239.84  Med: -217.49 Max: -195.14
Current: -239.84
-239.84
-195.14
Net-margin (%) -205.26
OPHT's Net-margin (%) is ranked lower than
62% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. OPHT: -205.26 )
Ranked among companies with meaningful Net-margin (%) only.
OPHT' s Net-margin (%) Range Over the Past 10 Years
Min: -283.02  Med: -244.14 Max: -205.26
Current: -205.26
-283.02
-205.26
ROE (%) -100.22
OPHT's ROE (%) is ranked lower than
81% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. OPHT: -100.22 )
Ranked among companies with meaningful ROE (%) only.
OPHT' s ROE (%) Range Over the Past 10 Years
Min: -246.64  Med: -112.18 Max: -78.3
Current: -100.22
-246.64
-78.3
ROA (%) -22.69
OPHT's ROA (%) is ranked higher than
53% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. OPHT: -22.69 )
Ranked among companies with meaningful ROA (%) only.
OPHT' s ROA (%) Range Over the Past 10 Years
Min: -231.01  Med: -39.72 Max: -23.27
Current: -22.69
-231.01
-23.27
ROC (Joel Greenblatt) (%) -1242.61
OPHT's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. OPHT: -1242.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPHT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -23793.04  Med: -12055.47 Max: -4920.45
Current: -1242.61
-23793.04
-4920.45
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

OPHT Guru Trades in Q2 2015

Jim Simons 473,350 sh (+21.62%)
» More
Q3 2015

OPHT Guru Trades in Q3 2015

Pioneer Investments 127,870 sh (New)
Jim Simons 377,500 sh (-20.25%)
» More
Q4 2015

OPHT Guru Trades in Q4 2015

Samuel Isaly 331,000 sh (unchged)
Jim Simons 301,415 sh (-20.15%)
Pioneer Investments 83,168 sh (-34.96%)
» More
2016

OPHT Guru Trades in 2016

Samuel Isaly 331,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 66.67
OPHT's Forward P/E is ranked lower than
88% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. OPHT: 66.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 27.45
OPHT's P/B is ranked lower than
94% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. OPHT: 27.45 )
Ranked among companies with meaningful P/B only.
OPHT' s P/B Range Over the Past 10 Years
Min: 7.11  Med: 15.55 Max: 46.11
Current: 27.45
7.11
46.11
P/S 31.88
OPHT's P/S is ranked lower than
72% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. OPHT: 31.88 )
Ranked among companies with meaningful P/S only.
OPHT' s P/S Range Over the Past 10 Years
Min: 18.75  Med: 33.09 Max: 53.57
Current: 31.88
18.75
53.57
Current Ratio 8.17
OPHT's Current Ratio is ranked higher than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OPHT: 8.17 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 8.17 Max: 34.54
Current: 8.17
0.34
34.54
Quick Ratio 8.17
OPHT's Quick Ratio is ranked higher than
70% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. OPHT: 8.17 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 8.17 Max: 34.54
Current: 8.17
0.34
34.54
Days Sales Outstanding 31.10
OPHT's Days Sales Outstanding is ranked higher than
78% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. OPHT: 31.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.49  Med: 19.80 Max: 31.1
Current: 31.1
8.49
31.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 27.45
OPHT's Price/Tangible Book is ranked lower than
92% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. OPHT: 27.45 )
Ranked among companies with meaningful Price/Tangible Book only.
OPHT' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.99  Med: 11.86 Max: 46.11
Current: 27.45
5.99
46.11
Price/Median PS Value 0.96
OPHT's Price/Median PS Value is ranked lower than
51% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. OPHT: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHT' s Price/Median PS Value Range Over the Past 10 Years
Min: 1.14  Med: 1.38 Max: 1.61
Current: 0.96
1.14
1.61
Earnings Yield (Greenblatt) (%) -9.10
OPHT's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. OPHT: -9.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.01  Med: 0.00 Max: 0
Current: -9.1
-11.01
0

More Statistics

Revenue(Mil) $52
EPS $ -3.05
Short Percentage of Float13.31%
52-Week Range $35.72 - 80.00
Shares Outstanding(Mil)35.25

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 32 272 500
EPS($) -6.09 0.70 2.80
EPS without NRI($) -6.09 0.70 2.80

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:O2T.Germany,
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the University of Southern... Apr 28 2016
Carmen A. Puliafito, MD, MBA, Former Dean of Keck School of Medicine of the University of Southern... Apr 28 2016
Coverage initiated on Ophthotech by Barclays Apr 27 2016
Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on... Apr 26 2016
Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on... Apr 26 2016
Ophthotech Corp. breached its 50 day moving average in a Bearish Manner : OPHT-US : April 21, 2016 Apr 21 2016
Ophthotech Corp. – Value Analysis (NASDAQ:OPHT) : April 8, 2016 Apr 08 2016
Ophthotech Corp. breached its 50 day moving average in a Bullish Manner : OPHT-US : April 7, 2016 Apr 07 2016
OPHTHOTECH CORP. Files SEC form 8-K, Change in Directors or Principal Officers Apr 01 2016
Ophthotech Corporation to Present at Barclays Global Healthcare Conference 2016 Mar 08 2016
OPHTHOTECH CORP. Financials Mar 04 2016
OPHTHOTECH CORP. Files SEC form 10-K, Annual Report Feb 26 2016
Ophthotech Corp. Earnings Analysis: 2015 By the Numbers Feb 25 2016
Edited Transcript of OPHT earnings conference call or presentation 24-Feb-16 1:00pm GMT Feb 24 2016
Ophthotech reports 4Q loss Feb 24 2016
Ophthotech reports 4Q loss Feb 24 2016
OPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 24 2016
Ophthotech Reports Fourth Quarter and Full Year 2015 Financial and Operating Results Feb 24 2016
Q4 2015 Ophthotech Corp Earnings Release - Before Market Open Feb 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK